Egashira Yusuke, Yoshimura Shinichi, Sakai Nobuyuki, Enomoto Yukiko
Neurol Med Chir (Tokyo). 2014;54 Suppl 2:32-9.
The present study aimed to demonstrate the “real-world” experiences of carotid artery stenting (CAS) in Japan using Japanese Registry of Neuroendovascular Therapy (JR-NET) 1 and 2, retrospective nationwide multi-center surveillances. JR-NET1 and 2 registries are retrospective surveillances conducted between January 2005 and December 2007 and January 2008 and December 2009, respectively, in Japan regarding neuroendovascular therapy. A total of 7,134 procedures (1,943 for JR-NET1 and 5,191 for JR-NET2) were included in this study and retrieved data were analyzed retrospectively. Treatment results of two surveillance periods were similar. In JR-NET2 registry, total of 5,191 lesions were treated by CAS and 5,008 of 5,191 procedures (96.5%) were performed by the board-certified surgeons of Japanese Society of Neuroendovascular Therapy. The rate of technical success was extremely high (99.99%), and the rate of clinically significant complication was low (3.2%). These results were comparable to a previous large study in Japan. Multivariate logistic analysis revealed that age [odds ratio (OR), 1.04 per year; 95% confidence interval (CI), 1.02–1.07; p=0.0004), symptomatic lesion (OR, 1.87; 95% CI; p=0.0004), and the use of closed-cell type stent (OR, 0.58; 95% CT, 0.32–1.00; p=0.05) were independently associated with clinically significant complications. It was revealed that good clinical results were achieved in patients who underwent CAS in Japan. It is expected that the evolution of devices and increasing experiences of surgeons would lead to further improvement of the clinical results, and further investigation would be required to clarify the optimal treatment strategy and therapeutic efficacy of CAS, especially in symptomatic lesions.
本研究旨在利用日本神经血管内治疗注册研究(JR-NET)1和2这两项全国性回顾性多中心监测,展示日本颈动脉支架置入术(CAS)的“真实世界”经验。JR-NET1和2注册研究分别是于2005年1月至2007年12月以及2008年1月至2009年12月在日本进行的关于神经血管内治疗的回顾性监测。本研究共纳入7134例手术(JR-NET1为1943例,JR-NET2为5191例),并对检索到的数据进行回顾性分析。两个监测期的治疗结果相似。在JR-NET2注册研究中,共有5191处病变接受了CAS治疗,5191例手术中有5008例(96.5%)由日本神经血管内治疗学会的认证外科医生实施。技术成功率极高(99.99%),具有临床意义的并发症发生率较低(3.2%)。这些结果与日本此前的一项大型研究相当。多因素逻辑分析显示,年龄[比值比(OR),每年1.04;95%置信区间(CI),1.02 - 1.07;p = 0.0004]、症状性病变(OR,1.87;95% CI;p = 0.0004)以及使用闭合细胞型支架(OR,0.58;95% CT,0.32 - 1.00;p = 0.05)与具有临床意义的并发症独立相关。结果显示,在日本接受CAS治疗的患者取得了良好的临床效果。预计器械的改进和外科医生经验的增加将使临床结果进一步改善,需要进一步研究以明确CAS的最佳治疗策略和治疗效果,尤其是在症状性病变方面。